Can

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Can

The medication Can is the proprietary name for the highly potent active ingredient Fluticasone Propionate. This substance is a prescription-only medicine (Rx) designed to provide localized relief from inflammation. It is often positioned for patients requiring consistent, targeted control of inflammatory symptoms.


Quick Facts

Property Description
Active Ingredient Fluticasone Propionate
Form Nasal spray, inhalation powder, cream, ointment
Pharmacological Class Glucocorticoid (Corticosteroid)
General Purpose Provides relief from localized inflammation and allergic response
Origin Synthetic Fluorinated Steroid Derivative

The Identity and Pharmacological Class of Can

The medicine known commercially as Can is defined by its active ingredient Fluticasone Propionate, which is categorized within the major pharmacological class of glucocorticoids, often referred to as corticosteroids. This substance is a potent synthetic compound, specifically a fluorinated steroid derivative, optimized to target and suppress inflammatory processes at the cellular level. As a glucocorticoid receptor agonist, it works primarily by inhibiting the release of chemical signals that trigger inflammation. Fluticasone propionate formulations possess a high receptor binding affinity, which supports effective localized anti-inflammatory activity.

Formulations, Application, and General Purpose

Fluticasone Propionate is prepared in several distinct dosage forms, including an aqueous suspension for nasal spray administration, an inhalation powder, and various topical preparations like cream or ointment. These preparations facilitate topical administration, meaning the active ingredient is delivered directly to the specific affected tissues, such as the nasal lining or skin. The general purpose of Can is to provide relief by effectively suppressing the symptoms caused by persistent, unwanted immune overactivity and localized inflammation. The local effects of fluticasone allow for therapeutic benefit while minimizing systemic exposure.

Regulatory References

  1. Fluticasone Topical: MedlinePlus Drug Information
  2. Topical Corticosteroids - StatPearls - NCBI Bookshelf

What side effects are possible with Can?

Possible Side Effects and Safety Information

The safety profile for Can (Fluticasone Propionate) is officially documented by government regulatory bodies (e.g., FDA, EMA) and is categorized by frequency and the organ system affected.

Adverse Reaction Frequencies

The most commonly reported adverse reactions are typically localized to the site of administration.

Frequency Classification (Regulatory Standard) Representative Adverse Reactions
Very Common Epistaxis (Nosebleeds)
Common Headache, Nasal irritation, Pharyngitis (Sore throat), Local Candidiasis
Very Rare Anaphylaxis, Adrenal suppression, Growth retardation in children

Systemic and Serious Safety Considerations

As a glucocorticoid, the medicine carries a documented risk of rare systemic corticosteroid effects, particularly with prolonged use or high doses. These risks involve the Endocrine system (e.g., Adrenal suppression, Hypercorticism) and Eye disorders (e.g., Glaucoma, Cataracts). Serious localized adverse reactions, such as Nasal Septal Perforation and severe Hypersensitivity Reactions (like Angioedema), are also explicitly listed in regulatory labeling.

Specific safety considerations exist for certain groups. For pediatric patients, the potential for growth retardation is a documented concern, requiring monitoring. Individuals with moderate to severe hepatic impairment may experience increased systemic exposure, raising the likelihood of systemic side effects. Furthermore, use is generally restricted until wound healing is complete following nasal trauma or surgery, due to the inhibitory effect of the active ingredient.

These safety domains structure the official understanding of the medicine’s risk profile, highlighting that while most reported effects are localized and frequent, rare but clinically significant systemic and structural risks are officially documented by regulatory authorities.

Overdose and Emergency Response

The official guidance for Can (Fluticasone Propionate) overdose is primarily concerned with the effects of prolonged use exceeding recommended doses, rather than acute toxicity. Acute overdosage is generally not expected to produce immediate adverse effects. Nonetheless, regulatory authorities mandate that individuals get medical help or contact a Poison Control Center right away in any instance of overdose.

The most significant risk from chronic high-dose exposure is the development of systemic corticosteroid effects, specifically adrenal suppression (Hypothalamic-Pituitary-Adrenal [HPA] axis suppression) and the manifestation of hypercorticism or Cushingoid features. Documented clinical signs may include unusual tiredness, weakness, or loss of appetite.

For patients with a history of prolonged high-dose use, the official label notes the critical risk of impaired adrenal response during periods of physical stress or emergency procedures, such as surgery. Additionally, a specific risk of growth retardation is documented for the pediatric and adolescent populations.

Management is supportive, as no specific antidote is officially documented. If systemic effects are observed, the dosage requires slow discontinuation following established medical protocols. The recovery of adrenal function can be formally verified by measuring plasma cortisol.

Therapeutic Uses of Can

The core therapeutic domain of acetaminophen (also known as paracetamol) is applied in addressing symptoms related to physical discomfort as an analgesic and in supporting the reduction of fever as an antipyretic. It is commonly used to help with temporarily easing physical discomfort and supporting the reduction of fever, and is considered relevant in contexts where short-term symptomatic assistance is needed.

The medication is relevant in contexts involving heightened systemic burden. This supportive relief may assist with managing symptoms related to inflammatory or irritative states and symptoms related to heightened physiological activity, such as those associated with common occurrences of headache, muscular ache, and discomfort. It is applied in clinical settings that involve acute or unstable symptom patterns, which may support general well-being during symptomatic phases. This medication may assist with managing the overall symptom load during episodes of heightened discomfort. It helps maintain a sense of stability when symptoms are more noticeable and is commonly used to help with temporary physiological imbalance. The benefit contributes to improved comfort during periods of heightened symptoms.


“...may help patients cope more steadily with symptom fluctuations.”


Quick Fact: Supports Easing of Physical Discomfort

This is relevant for managing symptom clusters that may become intense or disruptive, focusing on symptoms related to physical discomfort and systemic imbalance.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Can (Fluticasone Propionate) — Official Regulatory Information

This summary details the official population eligibility and non-eligibility for Fluticasone Propionate (Can), based strictly on authoritative government regulatory documents.


Eligibility Scope

Classification Eligible Populations Non-Eligible Populations
Adults and Age Adults and adolescents (ge 12 years). Pediatric patients aged 4 years and older (varies by specific formulation). Children younger than 4 years old (use safety/efficacy not established by regulators).
Contraindications N/A Patients with known hypersensitivity to the active substance or excipients. Patients with acute episodes of asthma (for inhaled formulations).

Eligibility-Related Restrictions

Official regulatory documents require caution or place restrictions on use in certain populations:

  • Wound Status: Use must be avoided until healing is complete after nasal surgery, trauma, or in the presence of unhealed nasal ulcers, due to the inhibitory effect of corticosteroids on wound healing.
  • Organ Function: Caution is advised for patients with severe hepatic impairment, as reduced liver function may increase systemic drug exposure.
  • Infections: Use requires caution in patients with active or quiescent infections, such as tuberculosis or systemic viral, fungal, or parasitic infections.
  • Pregnancy/Lactation: Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus; use during lactation is generally considered acceptable with caution.

The regulatory profile defines who can and cannot use the medicine by establishing clear contraindications that prohibit use, and by defining age minimums where safety has been established. Conditional eligibility is applied to patients with certain comorbidities or physiological states where caution and monitoring are mandated.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Fluticasone Propionate

Interaction Scope

Category Official Regulatory Statements for Fluticasone Propionate
Medicinal product categories with documented interactions Strong inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme system.
Specific interacting medicines (if explicitly listed) Ritonavir (potent CYP3A4 inhibitor); Ketoconazole (strong CYP3A4 inhibitor).
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction resulting from the inhibition of CYP3A4-mediated metabolism, the drug's primary clearance route.
Timing-based interaction rules (if applicable) None documented. Official labeling does not stipulate mandatory time separation requirements for co-administration.
Population-specific interaction notes (if applicable) Caution is explicitly noted for patients with severe hepatic disease, where the drug's slower clearance may increase systemic exposure and associated risk.
Interaction-related restrictions Co-administration with ritonavir is classified in official documents as not recommended or contraindicated due to the substantial and documented increase in systemic exposure.

Interaction Classifications (High-Level)

Classification Official Regulatory Statements for Fluticasone Propionate
Interaction severity classification (as defined in official documents) Contraindicated/Avoid Combination (Ritonavir); Use with Caution (Ketoconazole and other strong CYP3A4 inhibitors); Clinically Significant Increase in Exposure.
Regulatory basis (EMA / FDA / etc.) Interaction data is documented in official FDA Prescribing Information and EMA Summary of Product Characteristics.
Interaction-context constraints (as defined in official documents) The interaction applies to strong metabolic enzyme inhibitors and is defined by the resulting increase in AUC (Area Under the Curve) and Cmax (Maximum Concentration).

Resulting Interaction Structure

Official regulatory sources establish that the product's interaction profile is primarily defined by its dependency on the CYP3A4 enzyme for clearance. This metabolic vulnerability leads to strict restrictions on co-administration with other potent enzyme inhibitors, such as ritonavir, which significantly reduces the drug’s metabolic clearance and causes a substantial increase in systemic exposure. Furthermore, certain substances like Grapefruit Juice are noted in regulatory information to also inhibit this key metabolic pathway, potentially raising drug concentrations.

Mechanism of Action

How Can Works

Modulation of Receptor-Mediated Signaling

The drug acts within domains involving receptor-mediated signaling by specifically binding to and affecting key cell surface receptors, which are associated with heightened physiological responses. This engagement modifies early molecular steps to induce a modification of signal transduction equilibrium within these targeted pathways.


Regulation of Key Enzyme Pathways

[Drug Name] engages mechanisms that regulate overactive or dysregulated enzyme processes, particularly those driving the production of specific inflammatory or excitatory mediators. By doing so, it initiates signaling sequences that suppress mediator synthesis and reduces the magnitude of downstream effects resulting from mediator activity.


Influence on Physiological Cascades

The combined effect of receptor modulation and enzyme regulation contributes to altering pathway activity that may escalate under certain conditions. This modification modulates processes governed by distinct signaling patterns within the targeted biological systems, ultimately resulting in the mitigation of heightened physiological activity. The final mechanism influences feedback regulation within pathways, resulting in specific alterations to systemic physiological function.

Dosage and Administration Information

How to use Can (Fluticasone Propionate)

The application of Can (Fluticasone Propionate) is defined by official administration protocols that govern its route, dosage, frequency, and preparation. The regimen is designed for maintenance treatment and requires regular, consistent use rather than application on an as-needed basis.


Administration Scope

The medication is specifically approved for the Intranasal route (nasal spray) and the Orally Inhaled route (aerosols and powders).

Dosing Regimens:

  • Adult Nasal Spray: The standardized starting dosage is 200 micrograms per day, administered as a single daily dose or in two divided doses, often reducing to a 100 microgram per day maintenance dose.
  • Adult Inhalation (age ≥12): The typical starting dose is 88 micrograms twice daily, with the labeled maximum not to exceed 880 micrograms twice daily.

Age-Group Rules: Pediatric patients aged 4 years and older have distinct starting dosages, such as 100 micrograms once daily for the nasal spray.


Key Procedural Requirements

Preparation and Timing: Before first use or after a period of non-use, the nasal spray device must be primed, and the inhalation canister must be shaken well prior to each use. The medication is generally taken on a scheduled basis.

Procedural Steps:

  • Following use of the orally inhaled formulation, the patient is explicitly instructed to gargle and rinse the mouth with water.
  • In the event of a missed dose, the guidance is to not double the dose, but to continue with the next scheduled administration.
  • The total regimen is characterized by the need to titrate the amount used to the lowest effective dosage for long-term management.
  • The device must be discarded after the total labeled number of metered sprays has been administered.

Connection to the Overall Use Protocol

These official instructions establish a non-negotiable procedural framework that defines the exact administration route, the precise dose ranges for starting and maintenance, and mandatory steps for preparation and post-use care, ensuring adherence to the regulatory standard of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Can


Evidence for Nasal Formulations in Allergic Rhinitis

Research has explored the nasal spray form of Fluticasone Propionate (Can) in numerous Randomized Controlled Trials (RCTs) and systematic reviews for conditions characterized by seasonal and perennial allergies. These studies monitored short-term symptom changes in adults, adolescents, and children as young as four years old. Researchers tracked outcomes related to physical discomfort using the Total Nasal Symptom Score (TNSS). Findings described patterns observed in studies that related to measurements of daily functioning. What remains uncertain is the full picture of long-term outcomes and the sustained measurement patterns of outcomes beyond a typical one-year cycle.


Evidence for Inhaled Formulations in Persistent Asthma

The evidence base for the inhaled form includes a large number of RCTs and dose-ranging studies for persistent asthma. Researchers monitored objective pulmonary outcomes, such as Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF), and tracked the frequency of asthma exacerbations. Studies reported how symptoms evolved in the observed populations, and findings described patterns observed in the studies regarding these measurements. Data for older adults were included in many pivotal trials. Certainty remains low regarding the long-term effects of the highest doses, particularly in children.


Evidence in Special Populations

Research has explored the use of Fluticasone Propionate in pediatric populations across all formulations. In trials involving the inhaled form, research monitored growth velocity as an outcome measurement in children, with specific patterns observed across dose ranges. Dedicated subgroup findings for geriatric patients with multiple comorbidities are often uncertain due to modest sample sizes and heterogeneity across studies.

Key Studies & References

  1. Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial
  2. Flonase (fluticasone propionate) Nasal Spray Label

Frequently Asked Questions (FAQ)

Common questions about Can (FAQ)

Q: Is Can the same type of medicine as other treatments for the same condition?

A: No, Can (Fluticasone Propionate) is classified within the pharmacological class of glucocorticoids (a type of corticosteroid). This class of medicine is distinct from other treatments, such as antihistamines or decongestants, because it is classified by its action on inflammatory processes, according to official product information.

Q: Does Can interact with common pain relievers like ibuprofen?

A: Official regulatory documents emphasize a significant interaction risk with strong CYP3A4 inhibitors (metabolism blockers). Regulatory documents do not list common pain relievers like ibuprofen as strong inhibitors, which are the focus of formal warnings. The official information does not define formal restrictions for use with this class of drug.

Q: Is Can known to have an interaction with alcohol?

A: Official information generally does not list a direct chemical interaction between Fluticasone Propionate and alcohol. If the product is part of a combination medicine, there might be a general warning to limit or avoid alcohol consumption. This is a common precaution with many medications due to the potential for additive effects on the central nervous system (CNS).

Q: Can Can interact with birth control pills?

A: Regulatory documents primarily focus on warnings about strong CYP3A4 inhibitors. While birth control pills are not typically listed as a primary inhibitor, official documents note that interactions between corticosteroids and certain hormones are an area for careful consideration, though no formal contraindication is established.

Q: Is it possible for Can to pass into breast milk?

A: Glucocorticoids, including the active ingredient in Can, are known to be excreted in human milk following systemic use. Because systemic exposure is typically very low when the medicine is inhaled or used topically, the quantity present in breast milk is typically very low due to minimal systemic absorption.

Q: Why is Can prescribed for its approved use?

A: Can is prescribed for its approved uses because its active ingredient, Fluticasone Propionate, is a synthetic glucocorticoid that is described as suppressing inflammatory processes. In conditions like asthma or allergic rhinitis, this action is understood to reduce inflammation and swelling in the affected tissues, based on clinical study summaries.

Q: How quickly does Can usually start working?

A: The onset of effect is documented as occurring soon after the first dose. However, the official product information indicates that the full therapeutic benefit usually requires continued scheduled use over several days (typically 1 to 2 days) to achieve the maximum effect.

Q: What is the usual duration of action for a dose of Can?

A: Can is officially defined as a maintenance treatment intended for once or twice-daily scheduled use. This formulation supports scheduled, consistent use for maintenance treatment, rather than immediate, short-acting relief from symptoms.

Q: What should I know about taking Can with food?

A: Official instructions state there is no mandatory requirement to take the medicine with or without food. Because the nasal and inhaled formulations are delivered locally, food is unlikely to impact its absorption. However, the official instructions for the oral inhaled formulation require mouth rinsing with water after use to reduce the chance of localized side effects.

Q: Do I need to avoid any specific foods or drinks while using Can?

A: Yes, regulatory documents note that consumption of Grapefruit juice should be avoided or limited while using the medicine. Grapefruit juice is known to interfere with the body's clearance of the active ingredient, and official documents note that its consumption should be avoided or limited.

Q: Can Can affect my sleep patterns?

A: Adverse events related to sleep and behavior are categorized as very rare or not known in official regulatory documents. Official documents list sleep disorders, anxiety, and psychomotor hyperactivity as potential, though rare, side effects.

Q: What happens if I take Can with supplements like vitamins or herbs?

A: The primary interaction warning is about strong metabolic enzyme inhibitors. While vitamins are generally not an issue, some herbal supplements may affect this metabolic pathway. The regulatory documents require consideration of all concomitant use, including herbal products, to screen for potential interaction risks.

Q: Is Can generally suitable for older adults (seniors)?

A: Studies on the active ingredient included patients over 65 years of age, and official findings suggest no overall difference in effectiveness or safety compared to younger adults. Official information suggests that for older patients, the potential for decreased function in organs should be carefully monitored.

Q: How does Can compare to placebo in clinical trials?

A: Clinical trials for Can's approved uses indicated that the product showed a better measured outcome compared to placebo (an inactive substance) at improving key measurements. Studies tracked improvements in measures like total nasal symptom scores for rhinitis or objective pulmonary outcomes for asthma.

Q: Does Can affect liver function?

A: Official documents do not state that the medicine negatively affects a healthy liver itself. They do state that for patients with severe hepatic impairment (pre-existing poor liver function), careful monitoring is required due to the risk of increased systemic exposure.

Q: Are there any required lab tests while using Can?

A: Formal regulatory labeling advises that for patients using the medicine long-term, specific monitoring is warranted. This includes regulatory recommendations for periodic checks for the development of cataracts or glaucoma and for tracking growth velocity in pediatric patients.

Q: Does Can affect blood sugar levels?

A: Increases in blood glucose levels (hyperglycemia) are listed in official regulatory documents as a very rare adverse event. This is noted as a potential systemic effect associated with glucocorticoids and is considered in the context of patients with diabetes mellitus.

Q: Why do some people experience stomach upset with Can?

A: Official regulatory documents list stomach upset, including reactions like nausea and vomiting, as a common adverse reaction (up to 10% frequency) or very rare side effect, depending on the specific formulation. This official documentation describes why some individuals may report experiencing this issue.

Q: Does the time of day matter when taking Can?

A: The regulatory label indicates that for some formulations and dosing regimens, the total daily dose can be administered once daily or split into two divided doses. This suggests that flexibility exists for fitting the scheduled maintenance use into a consistent daily routine.

Q: Can Can cause a dry mouth?

A: Regulatory documents for some formulations list general side effects such as throat irritation or dryness. Specific post-marketing reports indicate dry mouth as a possible, though not commonly occurring, side effect associated with the use of the product.

Q: Are allergic reactions to Can common?

A: Hypersensitivity reactions are documented in official sources. Cutaneous (skin) hypersensitivity reactions are listed as uncommon (occurring in 0.1% to 1% of patients). More severe reactions like angioedema and anaphylaxis are officially listed as very rare (occurring in less than 0.01% of patients).

Q: How does Can impact mood or anxiety?

A: Psychiatric effects have been reported as a very rare or unknown frequency systemic effect, especially with high-dose or long-term use. These official reports include changes such as anxiety, sleep disorders, depression, and behavioral changes (e.g., hyperactivity, predominantly in children).

Q: Is Can available over the counter (OTC)?

A: Some low-dose nasal spray formulations containing the active ingredient Fluticasone Propionate are officially classified as an Over-the-Counter (OTC) medicine for temporary relief of allergy symptoms. Other formulations (such as inhalers) and higher strengths of the medicine remain available only by prescription.

Q: Are there restrictions on driving or operating machinery while on Can?

A: The regulatory documents for the active ingredient alone do not list formal driving restrictions. However, official precautions suggest avoiding engaging in activities requiring complete mental alertness if side effects like dizziness or somnolence are experienced.

Q: Can I crush or split the Can tablet/capsule?

A: Can is primarily administered as a nasal spray or inhalation aerosol/powder. Since the medicine is a nasal spray or inhaler, manipulation like crushing or splitting is not part of the administration procedure defined in the official instructions for use.

Q: Does Can have a Black Box Warning from the FDA?

A: The official FDA Prescribing Information for the active ingredient (Fluticasone Propionate) used as a monotherapy for its primary indications does not contain a Black Box Warning (formally known as a Boxed Warning) in the Highlights section.

Q: Is Can approved in countries outside of the US?

A: Yes, official regulatory documents, such as the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA), confirm that products containing Fluticasone Propionate are approved and regulated for use in countries outside of the United States.

How should Can be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of Can (Fluticasone Propionate). The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The medicine must be kept in a closed container, away from direct heat, sunlight, and moisture, and must not be frozen.

Storage of all medication, including this product, must be out of the sight and reach of children. Regarding disposal, all formulations have a documented in-use stability limit; for example, nasal spray bottles must be discarded after the labeled number of actuations is used. Unused or expired medication must be disposed of according to local regulations, and discharge into household drains or wastewater is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Can found in:

A-Z Index: